Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences (PLSE), specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced equity inducement grants to 14 new employees. The Compensation Committee approved stock options to purchase up to 165,300 shares of company common stock outside the 2017 Equity Incentive Plan, but under its terms.
The options were granted on February 27 and March 3, 2025, with exercise prices of $18.34 and $17.87 per share respectively, matching the closing prices on those dates. These equity awards feature a four-year time-based vesting schedule, with 25% vesting annually, contingent on continued employment.
Pulse Biosciences (PLSE), specializzata nella tecnologia Nanosecond Pulsed Field Ablation™ (nsPFA™), ha annunciato concessioni di azioni per 14 nuovi dipendenti. Il Comitato per la Compensazione ha approvato opzioni su azioni per acquistare fino a 165.300 azioni di azioni ordinarie della società al di fuori del Piano di Incentivazione Azionaria 2017, ma secondo i suoi termini.
Le opzioni sono state concesse il 27 febbraio e il 3 marzo 2025, con prezzi di esercizio di $18,34 e $17,87 per azione rispettivamente, corrispondenti ai prezzi di chiusura in quelle date. Questi premi azionari prevedono un programma di maturazione basato sul tempo di quattro anni, con il 25% che matura annualmente, subordinato al mantenimento dell'impiego.
Pulse Biosciences (PLSE), especializada en la tecnología Nanosecond Pulsed Field Ablation™ (nsPFA™), ha anunciado concesiones de acciones para 14 nuevos empleados. El Comité de Compensación aprobó opciones de acciones para comprar hasta 165,300 acciones de acciones ordinarias de la compañía fuera del Plan de Incentivos de Capital de 2017, pero bajo sus términos.
Las opciones se otorgaron el 27 de febrero y el 3 de marzo de 2025, con precios de ejercicio de $18.34 y $17.87 por acción respectivamente, coincidiendo con los precios de cierre en esas fechas. Estos premios de capital cuentan con un programa de adquisición basado en el tiempo de cuatro años, con un 25% que se adquiere anualmente, condicionado a la continuidad del empleo.
Pulse Biosciences (PLSE)는 Nanosecond Pulsed Field Ablation™ (nsPFA™) 기술을 전문으로 하며, 14명의 신규 직원에게 주식 유인 보상을 발표했습니다. 보상 위원회는 2017년 주식 인센티브 계획 외에서 회사의 보통주 165,300주를 구매할 수 있는 주식 옵션을 승인했습니다.
옵션은 2025년 2월 27일과 3월 3일에 부여되었으며, 각각 $18.34 및 $17.87의 행사 가격으로, 해당 날짜의 종가와 일치합니다. 이 주식 보상은 4년의 시간 기반 성과 일정을 특징으로 하며, 25%가 매년 성과 조건에 따라 부여됩니다.
Pulse Biosciences (PLSE), spécialisée dans la technologie Nanosecond Pulsed Field Ablation™ (nsPFA™), a annoncé des attributions d'actions pour 14 nouveaux employés. Le Comité de Rémunération a approuvé des options d'achat d'actions pour acquérir jusqu'à 165 300 actions de l'action ordinaire de l'entreprise en dehors du Plan d'Incentive en Actions de 2017, mais selon ses termes.
Les options ont été accordées le 27 février et le 3 mars 2025, avec des prix d'exercice de $18,34 et $17,87 par action respectivement, correspondant aux prix de clôture à ces dates. Ces attributions d'actions comportent un calendrier de maturation basé sur le temps de quatre ans, avec 25 % de maturation annuellement, conditionné à la poursuite de l'emploi.
Pulse Biosciences (PLSE), das auf die Technologie Nanosecond Pulsed Field Ablation™ (nsPFA™) spezialisiert ist, hat Aktienanreize für 14 neue Mitarbeiter angekündigt. Der Vergütungsausschuss genehmigte Aktienoptionen zum Kauf von bis zu 165.300 Aktien der Stammaktien des Unternehmens außerhalb des Equity Incentive Plans von 2017, jedoch gemäß dessen Bedingungen.
Die Optionen wurden am 27. Februar und 3. März 2025 gewährt, mit Ausübungspreisen von $18,34 und $17,87 pro Aktie, die den Schlusskursen an diesen Tagen entsprechen. Diese Eigenkapitalvergaben sehen einen vierjährigen zeitbasierten Vesting-Plan vor, bei dem 25% jährlich fällig werden, abhängig von der fortgesetzten Beschäftigung.
- Employee expansion with 14 new hires indicates company growth
- Potential dilution from 165,300 new stock options
Pulse has awarded inducement options to 14 new employees to purchase up to 165,300 shares of Company common stock. The Company’s independent compensation committee approved these awards as an inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of either
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304049146/en/
Investors:
Pulse Biosciences, Inc.
Jon Skinner, CFO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
FAQ
How many shares were granted in Pulse Biosciences' (PLSE) inducement awards in March 2025?
What are the exercise prices for PLSE's March 2025 inducement stock options?
What is the vesting schedule for PLSE's 2025 inducement stock options?
Under which plan were PLSE's March 2025 inducement grants issued?
